3-methylamino-5-phenyl-pyrazine-2-carboxylic acid methyl ester | 108539-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-methylamino-5-phenyl-pyrazine-2-carboxylic acid methyl ester
• 英文别名: 3-Methylamino-5-phenyl-pyrazin-2-carbonsaeure-methylester；Methyl 3-(methylamino)-5-phenylpyrazine-2-carboxylate
• CAS: 108539-92-0
• 化学式: C₁₃H₁₃N₃O₂
• 分子量: 243.265
• InChiKey: VSZFYZCGLSRASB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-methylamino-5-phenyl-pyrazine-2-carboxylic acid methyl ester 在 乙醇 、 氨 作用下， 生成 (3-cyano-6-phenyl-pyrazin-2-yl)-methyl-carbamic acid ethyl ester
  参考文献：
  名称：

  Inappropriate Use of Digoxin in Older Hospitalized Heart Failure Patients

  摘要：

  Background. Older adults are more likely to suffer from the adverse effects of digoxin. Studies have described the inappropriate use of digoxin in various populations, The objective of this study was to determine the correlates of inappropriate digoxin use in older heart failure patients.Methods. We studied older hospitalized heart failure patients with documented left ventricular (LV) function evaluation and electrocardiography. Digoxin use was considered inappropriate if patients had preserved LV systolic function (ejection fraction greater than or equal to40%) or if they had no atrial fibrillation (AF). We compared baseline patient characteristics by indication for digoxin and tested statistical significance using Pearson's chi-square analysis and Student's t tests. using logistic regression, we determined the correlates of inappropriate use and initiation of digoxin.Results. Subjects (N = 603) had a mean age of 79 (+/-7) years; 59% were women, and 18% were African American. A total of 376 patients (62%) were discharged on dioxin, and 223 (37%) had no indication for its use. Half of the patients without an indication for digoxin received the drug. Of 132 patients without an indication and not already on digoxin, 38 (29%) were initiated on it. After adjustment for various patient and care characteristics, prior digoxin use (adjusted odds ratio [OR] 11.47, 95% confidence internal [CI] 5.72-23.02) and pulse greater than or equal to100/min (adjusted OR 2.33, 95% CI 1.10-4.94) were associated with inappropriate digoxin use. Pulse greater than or equal to100/min was also associated with inappropriate initiation of the drug (adjusted OR 2.95. 95% CI 1.28-6.78).Conclusions. Inappropriate use of dioxin was common and was associated with prior use. Tachycardia was associated with inappropriate use and initiation. Electrocardiography and echocardiography should be performed in all older heart failure patients. Digoxin therapy should not be initiated or continued in patients without any evidence of LV systolic dysfunction or chronic AF.

  DOI：

  10.1093/gerona/57.2.m138
• 作为产物：
  描述：

  methyl 5-phenyl-3-(2,2,2-trifluoro-N-methylacetamido)pyrazine-2-carboxylate 、 sodium methylate 在 氮气 、 二氯甲烷 、 magnesium sulfate 作用下， 以 甲醇 、 二氯甲烷 、 Brine 为溶剂， 反应 1.5h， 以affording 179 mg (99%) of methyl 3-(methylamino)-5-phenylpyrazine-2-carboxylate as a yellow solid的产率得到3-methylamino-5-phenyl-pyrazine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Diazaquinolones that inhibit prolyl hydroxylase activity

  摘要：

  式I的化合物是HIF脯氨酸羟化酶的有用抑制剂。式I的化合物具有以下结构：其中变量的定义在此提供。

  公开号：

  US20090099171A1

文献信息

• DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY
  申请人：Amgen, Inc

  公开号：EP2155746A2

  公开（公告）日：2010-02-24
• US8097620B2
  申请人：——

  公开号：US8097620B2

  公开（公告）日：2012-01-17
• [EN] DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY<br/>[FR] DIAZAQUINOLONES INHIBANT L'ACTIVITÉ DE LA PROLYL HYDROXYLASE
  申请人：AMGEN INC

  公开号：WO2008137084A2

  公开（公告）日：2008-11-13

  [EN] Compounds of Formula (I) are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure where the definitions of the variables are provided herein.
  [FR] L'invention porte sur des composés de formule (I) inhibiteurs des HIF prolyl hydroxylases présentant la structure suivante et dont la définition des variables se trouve dans la description.
• Inappropriate Use of Digoxin in Older Hospitalized Heart Failure Patients
  作者：A. Ahmed、R. M. Allman、J. F. DeLong

  DOI：10.1093/gerona/57.2.m138

  日期：2002.2.1

  Background. Older adults are more likely to suffer from the adverse effects of digoxin. Studies have described the inappropriate use of digoxin in various populations, The objective of this study was to determine the correlates of inappropriate digoxin use in older heart failure patients.Methods. We studied older hospitalized heart failure patients with documented left ventricular (LV) function evaluation and electrocardiography. Digoxin use was considered inappropriate if patients had preserved LV systolic function (ejection fraction greater than or equal to40%) or if they had no atrial fibrillation (AF). We compared baseline patient characteristics by indication for digoxin and tested statistical significance using Pearson's chi-square analysis and Student's t tests. using logistic regression, we determined the correlates of inappropriate use and initiation of digoxin.Results. Subjects (N = 603) had a mean age of 79 (+/-7) years; 59% were women, and 18% were African American. A total of 376 patients (62%) were discharged on dioxin, and 223 (37%) had no indication for its use. Half of the patients without an indication for digoxin received the drug. Of 132 patients without an indication and not already on digoxin, 38 (29%) were initiated on it. After adjustment for various patient and care characteristics, prior digoxin use (adjusted odds ratio [OR] 11.47, 95% confidence internal [CI] 5.72-23.02) and pulse greater than or equal to100/min (adjusted OR 2.33, 95% CI 1.10-4.94) were associated with inappropriate digoxin use. Pulse greater than or equal to100/min was also associated with inappropriate initiation of the drug (adjusted OR 2.95. 95% CI 1.28-6.78).Conclusions. Inappropriate use of dioxin was common and was associated with prior use. Tachycardia was associated with inappropriate use and initiation. Electrocardiography and echocardiography should be performed in all older heart failure patients. Digoxin therapy should not be initiated or continued in patients without any evidence of LV systolic dysfunction or chronic AF.
• Diazaquinolones that inhibit prolyl hydroxylase activity
  申请人：Allen Jennifer R.

  公开号：US20090099171A1

  公开（公告）日：2009-04-16

  Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  式I的化合物是HIF脯氨酸羟化酶的有用抑制剂。式I的化合物具有以下结构：其中变量的定义在此提供。